Welcome to our dedicated page for Steris Plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for STERIS plc (NYSE: STE) provide detailed regulatory information about this Ireland-incorporated medical technology company, which focuses on products and services that support patient care with an emphasis on infection prevention. Through its filings, STERIS discloses financial results, governance decisions, executive transitions and shareholder meeting outcomes, giving investors a structured view of the company’s regulatory history.
Current reports on Form 8-K filed by STERIS include items on Results of Operations and Financial Condition, where the company furnishes press releases announcing quarterly financial results. These filings reference segment performance for Healthcare, Applied Sterilization Technologies (AST) and Life Sciences, and describe the use of non-GAAP measures such as adjusted net income, adjusted earnings per diluted share, free cash flow, organic revenue growth and constant currency organic revenue growth.
Other 8-K filings address Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, detailing transitions in the Chief Financial Officer role and related compensation and equity arrangements. Filings also summarize matters submitted to a vote of security holders, including the election of directors, appointment and remuneration of auditors, advisory votes on executive compensation and renewals of the Board’s authority to issue shares and opt out of statutory pre-emption rights under Irish law.
On this page, investors can review STERIS’s SEC reports alongside AI-powered summaries that explain the key points of each filing, highlight important sections and clarify technical language. Real-time updates from EDGAR ensure that new Forms 8-K and other reports appear promptly. Users can quickly identify filings related to quarterly earnings (such as 8-Ks furnishing press releases), governance and compensation topics, and other material events that shape STERIS’s financial and corporate profile.
STERIS plc reported solid growth for the nine months ended December 31, 2025. Total revenues rose to $4,347.5 million from $3,979.0 million, with balanced increases in Healthcare, AST, and Life Sciences. Net income attributable to shareholders grew to $562.1 million, and diluted EPS from continuing operations increased to $5.69 from $4.68.
Gross profit reached $1,929.4 million, while operating income from continuing operations improved to $785.0 million, despite $5.1 million of acquisition and integration expenses and $3.0 million of restructuring costs. Cash flow from operating activities was strong at $1,006.0 million, supporting capital expenditures of $278.8 million and share repurchases of $161.2 million plus $180.0 million in dividends.
The balance sheet showed cash and cash equivalents of $423.7 million and total debt of $1,898.4 million, with shareholders’ equity rising to $7,154.5 million. The company completed the Dental segment sale (reported as discontinued operations) and continues to manage restructuring in its Healthcare surgical business in Europe and an ethylene oxide litigation settlement framework in Illinois, as well as ongoing IRS tax matters.
STERIS plc filed a current report stating that it has released financial results for its fiscal 2026 third quarter, covering the quarter ended December 31, 2025. The company announced these results through a press release dated February 4, 2026, which is attached as Exhibit 99.1 and furnished, rather than filed, with regulators.
STERIS plc filed a Form 4 reporting an equity award to a company officer. On January 2, 2026, a STERIS officer serving as VP, Chief Comp. & Quality Officer acquired 798 ordinary shares of STERIS plc at a reported price of $0 per share, indicating a share grant rather than an open-market purchase.
After this transaction, the officer beneficially owned 5,028 ordinary shares directly, of which 3,750 shares were restricted as of January 2, 2026. These restricted shares are scheduled to vest in tranches between May 31, 2026 and January 2, 2029. In addition, units representing 248 ordinary share equivalents were held for the officer under the STERIS Corporation 401(k) Plan as of that same date.
STERIS plc executive John P. Ubbing, Vice President, Chief Compliance & Quality Officer, reports his beneficial ownership in the company as of early 2026. He directly holds 4,230 ordinary shares, of which 2,952 are restricted. These restrictions are scheduled to lapse in stages: 660 shares on May 31, 2026; 1,128 shares on June 2, 2026; 588 shares on June 4, 2027; and 576 shares on June 3, 2028.
In addition, Ubbing has an indirect interest in 248 ordinary share equivalents held for him under the STERIS Corporation 401(k) Plan. He also holds several employee stock options: 2,480 options at an exercise price of
STERIS plc (STE) reported insider transactions by its Sr. VP and GM, Life Sciences, on November 21, 2025. The officer exercised employee stock options to buy 2,872 ordinary shares at $114.22 and 2,136 ordinary shares at $147.05, then sold the same numbers of shares in two sales at $262 per share. Following these transactions, the officer beneficially owned 10,710 ordinary shares.
As of November 21, 2025, 4,003 of these 10,710 ordinary shares are restricted, with restrictions scheduled to lapse in several tranches between June 1, 2026 and June 5, 2028. The reported stock options are described as fully vested and now show 0 derivative securities remaining after the exercises.
STERIS plc (STE) insider filed a Form 144 to sell 5,008 ordinary shares. The planned sale is through Charles Schwab & Co., Inc. on the NYSE, with an approximate sale date of 11/21/2025. The shares listed have an aggregate market value of $1,312,096.00, and the table notes 98,147,009 shares outstanding. The seller acquired these shares on 11/21/2025 through an employee stock option exercise, using a broker payment for a cashless exercise.
STERIS plc (STE) officer and V.P. & Corporate Treasurer reported option exercises and share sales. On November 18, 2025, the insider exercised an employee stock option for 3,536 ordinary shares at an exercise price of $182.22 per share, then sold shares in several transactions at market prices around the mid-$250s. Reported sales included 3,324 shares at a weighted average price of $257.43, 212 shares at a weighted average price of $258.03, and 1,500 shares at $257.76 per share.
After these transactions, the reporting person beneficially owned 5,695 ordinary shares, including 1,475 restricted shares as of November 18, 2025. The restricted shares are scheduled to vest in installments between June 1, 2026 and June 5, 2028, and the reported stock option is now fully vested with no remaining balance.
STERIS plc (STE)5,036 ordinary shares. The planned sale, through Charles Schwab & Co., Inc., has an aggregate market value of $1,297,033 and is expected to occur around 11/18/2025 on the NYSE. The company reports 98,147,009 shares outstanding, so this planned sale represents a small portion of total shares.
The securities to be sold were acquired mainly through equity compensation from STERIS plc, including an employee stock option exercise of 3,536 shares on 11/18/2025 via a broker-assisted cashless exercise and several restricted stock lapses between 05/31/2023 and 10/01/2024. The notice also reports that the same holder sold 3,204 shares of STERIS on 08/20/2025 for gross proceeds of $798,560 in the past three months.
STERIS plc (STE) Form 4: The company’s Senior Vice President, General Counsel and Secretary exercised 15,000 employee stock options at $69.72 per share on 11/11/2025 and sold 15,000 ordinary shares the same day at a weighted average price of $265.14 (range $265.00–$265.95). Following these transactions, the officer directly owned 33,669 shares as of 11/11/2025. Of these, 8,511 are restricted, with scheduled lapses through June 2028.
STERIS plc received a Form 144 notice for a proposed sale of 15,000 Ordinary shares. The filing lists an aggregate market value of $3,977,050 and an approximate sale date of 11/11/2025. The designated broker is Charles Schwab & Co., Inc., and the shares are to be sold on the NYSE.
The shares were acquired on 11/11/2025 via an employee stock option exercise with a broker payment for cashless exercise. This notice reflects an intended disposition by a holder under Rule 144.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
